|
Samuel E. Lynch, D.M.D., D.M.Sc. is a founder of BioMimetic and has served as President, Chief Executive Officer and a director since its inception. Dr. Lynch served as Chairman of BioMimetic's board of directors from inception until August 2005. Prior to founding BioMimetic, Dr. Lynch spent over four years at Luitpold Pharmaceuticals, Inc., a US subsidiary of Sankyo, Co., Ltd. as Vice President with P&L responsibility for the Osteohealth Co., a division focused on bone and tissue regeneration. Dr. Lynch successfully managed all aspects of the business, including sales, marketing, clinical development and G&A functions, resulting in a "turn-around" and conversion into a highly profitable business. Prior to joining Sankyo Luitpold, Dr. Lynch was the Executive Director for Research and Development for the Institute of Molecular Biology, a private research institute affiliated with Harvard University, where he directed research in bone and tissue healing. He concurrently served on the faculty at Harvard School of Dental Medicine for six years, from which he earlier received a Certificate of Specialty in Periodontology. Dr. Lynch also received a Doctorate of Medical Sciences from the Harvard Medical School. In addition to his industry success, Dr. Lynch has a long record of scientific accomplishments, has published and lectured extensively and is a co-inventor of BioMimetic's technologies. | 